Pozen's (POZN - commentary - Cramer's Take) shares rose

Pozen's (POZN - commentary - Cramer's Take) shares rose after the company said that migraine sufferers who were treated early with its drug Trexima remained pain-free longer than those who were treated late, according to analyses of four separate trials. Shares were up 1.8% to $12.55.